Literature DB >> 33026566

Association between the rs3751143 polymorphism of P2RX7 gene and chronic lymphocytic leukemia: A meta-analysis.

Wen-Jun Zhang1, Zheng-Ming Zhu2.   

Abstract

OBJECTIVES: Meta-analysis was used to determine the association between rs3751143 polymorphism of P2RX7 gene and the risk of chronic lymphocytic leukemia (CLL).
METHODS: Search for published articles about the association between the rs3751143 and CLL in PubMed, MEDINE, Web of Science, and Embase databases, with a calculated odds ratio of (OR) and 95% confidence interval (95%CI).
RESULTS: A total of 1184 cases and 1725 controls in 8 studies were pooled together for evaluation of the overall association between rs3751143 and risk of CLL. Allele model (A vs C, p = 0.16, OR = 0.85, 95%CI = 0.71-1.17), homozygous model (AA vs CC, p = 0.07; OR = 0.78, 95%CI = 0.84-1.08), and heterozygous model (AC vs CC, p = 0.76; OR = 0.85; 95%CI = 0.68-0.79) did not show decreased risk of developing CLL. Similarly, dominant model (AA + AC vs. CC: p = 0.58; OR = 1.10, 95%CI = 0.69-1.75), and recessive model (AA vs AC + CC, p = 0.21, OR = 1.18, 95%CI = 0.70-1.99) failed to show decreased risk of developing CLL. However, in familial, heterozygous model (AC vs. CC: p = 0.0006, OR = 0.64, 95%CI = 0.67-1.50) and recessive model (AA vs. AC + CC: p = 0.0017; OR = 1.02, 95%CI = 0.73-2.35) indicated the association between the inheritance of rs3751143 and the risk of developing CLL. In the overall survival prognosis, no significant association between rs3751143 and CLL was detected with relatively high heterogeneity.
CONCLUSIONS: Our pooled data indicates that there is a correlation between the inheritance of rs3751143 and the risk of CLL in familial.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Meta-analysis; P2X7 receptor (P2RX7); rs3751143 polymorphism

Year:  2020        PMID: 33026566      PMCID: PMC7855105          DOI: 10.1007/s11302-020-09737-8

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  28 in total

1.  Association of the 1513C polymorphism in the P2X7 gene with familial forms of chronic lymphocytic leukaemia.

Authors:  Lan-Phuong Dao-Ung; Stephen J Fuller; Ronald Sluyter; Kristen K SkarRatt; Ulf Thunberg; Gerard Tobin; Karen Byth; Maria Ban; Richard Rosenquist; Graeme J Stewart; James S Wiley
Journal:  Br J Haematol       Date:  2004-06       Impact factor: 6.998

2.  Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk.

Authors:  Dalemari Crowther-Swanepoel; Mahmoud Mansouri; Anna Enjuanes; Ana Vega; Karin E Smedby; Clara Ruiz-Ponte; Jesper Jurlander; Gunnar Juliusson; Emilio Montserrat; Daniel Catovsky; Elias Campo; Angel Carracedo; Richard Rosenquist; Richard S Houlston
Journal:  Br J Haematol       Date:  2010-06-10       Impact factor: 6.998

3.  Synopsis and synthesis of candidate-gene association studies in chronic lymphocytic leukemia: the CUMAGAS-CLL information system.

Authors:  Elias Zintzaras; George D Kitsios
Journal:  Am J Epidemiol       Date:  2009-08-21       Impact factor: 4.897

4.  A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor.

Authors:  B J Gu; W Zhang; R A Worthington; R Sluyter; P Dao-Ung; S Petrou; J A Barden; J S Wiley
Journal:  J Biol Chem       Date:  2001-01-09       Impact factor: 5.157

Review 5.  The role and pharmacological properties of the P2X7 receptor in neuropathic pain.

Authors:  Wen-Jun Zhang; Zheng-Ming Zhu; Zeng-Xu Liu
Journal:  Brain Res Bull       Date:  2019-11-25       Impact factor: 4.077

6.  A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes.

Authors:  Giulio Cabrini; Simonetta Falzoni; Sylvia L Forchap; Patrizia Pellegatti; Alessandra Balboni; Paola Agostini; Antonio Cuneo; Gianluigi Castoldi; O Roberto Baricordi; Francesco Di Virgilio
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

7.  A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular study.

Authors:  James S Wiley; L Phuong Dao-Ung; Ben J Gu; Ronald Sluyter; Anne N Shemon; Changping Li; John Taper; John Gallo; Arumugam Manoharan
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

8.  Lack of association of 1513 A/C polymorphism in P2X7 gene with susceptibility to pulmonary and extrapulmonary tuberculosis.

Authors:  Fethi Ahmet Ozdemir; Deniz Erol; Vahit Konar; Hüseyin Yüce; Ebru Kara Şenli; Funda Bulut; Figen Deveci
Journal:  Tuberk Toraks       Date:  2014

9.  P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12.

Authors:  L Y Zhang; R E Ibbotson; J A Orchard; A C Gardiner; R V Seear; A J Chase; D G Oscier; N C P Cross
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

10.  P2X7 promotes the progression of MLL-AF9 induced acute myeloid leukemia by upregulation of Pbx3.

Authors:  Wenli Feng; Xiao Yang; Lina Wang; Rong Wang; Feifei Yang; Hao Wang; Xiaoli Liu; Qian Ren; Yingchi Zhang; Xiaofan Zhu; Guoguang Zheng
Journal:  Haematologica       Date:  2021-05-01       Impact factor: 9.941

View more
  2 in total

1.  A loss-of-function polymorphism in ATG16L1 compromises therapeutic outcome in head and neck carcinoma patients.

Authors:  Julie Le Naour; Zsofia Sztupinszki; Vincent Carbonnier; Odile Casiraghi; Virginie Marty; Lorenzo Galluzzi; Zoltan Szallasi; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2022-04-17       Impact factor: 7.723

2.  Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.

Authors:  Natasha Monte; Karla B C C Pantoja; Juliana C G Rodrigues; Darlen C de Carvalho; Tereza C B Azevedo; Esdras E B Pereira; Paulo P de Assumpção; Sidney E B Dos Santos; Marianne R Fernandes; Ney P C Dos Santos
Journal:  Mol Genet Genomic Med       Date:  2021-05-29       Impact factor: 2.183

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.